Latest Innovation News

CurveBeam AI has received $5.6 million of its $6.5 million placement, issuing shares for the settled tranche while awaiting the remaining offshore transfer. The company plans to complete the share issuance once the final funds arrive.

DigitalX Limited is ramping up its Bitcoin accumulation efforts by expanding trading activities and launching new Bitcoin-related products, aiming to reach 2,100 BTC by 2027.

DroneShield is investing $13 million over three years to open a new counter-drone research facility in Adelaide, marking a key step in its global growth and technology development.

Acusensus Limited has landed its first major automated enforcement contract in the US with Connecticut, marking a significant milestone in its American growth strategy. The five-year deal, valued at US$22.6 million, will see the deployment of AI-enabled speed enforcement technology across work zones.

dorsaVi reports a striking 15-fold increase in US Physical Therapy clinic subscriptions for its ViMove+ product, driven by strong surgeon endorsements and a successful face-to-face training rollout.

Micro-X Ltd has received a $5.08 million R&D tax incentive rebate for FY25, with an additional $0.31 million pending approval, reinforcing its innovation-driven growth in medical imaging technology.

Stakk Limited has successfully raised $15 million through an oversubscribed equity placement, underscoring strong institutional confidence in its Embedded Finance growth strategy. The funds will accelerate expansion in the U.S. and Australian markets as the company’s recurring revenue surges.

Lithium Universe and Macquarie University have unveiled a breakthrough electrode design that dramatically improves silver recovery from end-of-life solar panels, promising higher efficiency and sustainability in recycling.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.

Energy One Limited has appointed Benjamin Tranier as CEO (Designate), set to take the helm in March 2026, marking a strategic leadership transition aligned with its global expansion ambitions.

Opthea Limited has received a substantial A$10.8 million R&D tax incentive from the Australian government, reinforcing its commitment to advancing its novel drug candidate sozinibercept. This funding milestone underscores the company’s strategic focus on innovation and fiscal discipline.